Skip to main content

Coherus BioSciences Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

CHRS$0.64-21.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Deficit

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders'
​ · Shares · ​ · Amount · Capital · Loss · Deficit · Deficit
Balances at December 31, 2023112,215,260​$11​$1,386,312​$(248)​$(1,579,500)​$(193,425)
Net income​—​—​—​—​102,875​102,875
Issuance of common stock upon exercise of stock options​174,651​—​291​—​—​291
Issuance of common stock upon vesting of restricted stock units ("RSUs")​741,213​—​—​—​—​—
Issuance of common stock under ATM Offering, net of issuance costs​650,005​​—​​1,507​​—​​—​​1,507
Taxes paid related to net share settlement of RSUs​(284,275)​​—​​(745)​​—​​—​​(745)
Stock-based compensation expense​—​—​7,677​—​—​7,677
Other comprehensive loss, net of tax—​—​—​(24)​—​(24)
Balances at March 31, 2024113,496,854​​11​​1,395,042​​(272)​​(1,476,625)​​(81,844)
Net loss—​—​—​—​(12,921)​(12,921)
Issuance of common stock upon vesting of RSUs​21,583​—​—​—​—​—
Issuance of common stock - partial payout of 2023 bonus in RSUs​1,976,750​​1​​4,407​​—​​—​​4,408
Offering costs associated with ATM Offering​—​​—​​(52)​​—​​—​​(52)
Taxes paid related to net share settlement of RSUs​(767,971)​​—​​(1,711)​​—​​—​​(1,711)
Issuance of common stock under the employee stock purchase plan ("ESPP")471,439​—​685​—​—​685
Stock-based compensation expense—​—​7,327​—​—​7,327
Balances at June 30, 2024115,198,655​$12​$1,405,698​$(272)​$(1,489,546)​$(84,108)
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders'
​ · Shares · ​ · Amount · Capital · Loss · Deficit · Deficit
Balances at December 31, 202278,851,516​$8​$1,204,431​$(249)​$(1,341,608)​$(137,418)
Net loss—​—​—​—​(75,729)​(75,729)
Issuance of common stock upon exercise of stock options24,107​—​103​—​—​103
Issuance of common stock upon vesting of RSUs771,167​—​—​—​—​—
Issuance of common stock under ATM Offering, net of issuance costs​1,131,450​​—​​7,059​​—​​—​​7,059
Taxes paid related to net share settlement of RSUs​(289,944)​​—​​(2,781)​​—​​—​​(2,781)
Stock-based compensation expense—​—​12,288​—​—​12,288
Other comprehensive loss, net of tax—​—​—​(29)​—​(29)
Balances at March 31, 202380,488,296​​8​​1,221,100​​(278)​​(1,417,337)​​(196,507)
Net loss—​—​—​—​(42,869)​(42,869)
Issuance of common stock upon exercise of stock options8,182​—​14​—​—​14
Issuance of common stock upon vesting of RSUs​142,982​—​—​—​—​—
Issuance of common stock under Public Offering, net of issuance costs​13,529,411​​1​​53,624​​—​​—​​53,625
Offering costs associated with ATM offering​—​​—​​(74)​​—​​—​​(74)
Taxes paid related to net share settlement of RSUs​(48,529)​​—​​(305)​​—​​—​​(305)
Issuance of common stock under the ESPP321,672​—​1,337​—​—​1,337
Stock-based compensation expense—​—​10,034​—​—​10,034
Other comprehensive loss, net of tax​—​​—​​—​​(19)​​—​​(19)
Balances at June 30, 202394,442,014​$9​$1,285,730​$(297)​$(1,460,206)​$(174,764)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.